{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:35:56Z","timestamp":1787589356663,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00253-023-12545-w","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T09:02:17Z","timestamp":1682931737000},"page":"3495-3508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Design and characterization of chimeric Rabies-SARS-CoV-2 virus-like particles for vaccine purposes"],"prefix":"10.1007","volume":"107","author":[{"given":"Ernesto","family":"Garay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5109-7637","authenticated-orcid":false,"given":"Diego","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Villarraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonela","family":"Fuselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Antu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Tardivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Celeste","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Battagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Cassataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ceaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"12545_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/acsphotonics.1c01154","volume":"9","author":"M Arista-Romero","year":"2021","unstructured":"Arista-Romero M, Delcanale P, Pujals S, Albertazzi L (2021) Nanoscale mapping of recombinant viral proteins: from cells to virus-like particles. ACS Photonics 9:101\u2013109. https:\/\/doi.org\/10.1021\/acsphotonics.1c01154","journal-title":"ACS Photonics"},{"key":"12545_CR2","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1016\/j.vaccine.2020.03.001","volume":"38","author":"S Aston-Deaville","year":"2020","unstructured":"Aston-Deaville S, Carlsson E, Saleem M, Thistlethwaite A, Chan H, Maharjan S, Facchetti A, Feavers IM, Alistair Siebert C, Collins RF, Roseman A, Derrick JP (2020) An assessment of the use of hepatitis B virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis. Vaccine 38:3201\u20133209. https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.001","journal-title":"Vaccine"},{"key":"12545_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMOA2035389\/SUPPL_FILE\/NEJMOA2035389_DATA-SHARING.PDF","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403\u2013416. https:\/\/doi.org\/10.1056\/NEJMOA2035389\/SUPPL_FILE\/NEJMOA2035389_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"12545_CR4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Cohen C, Hern\u00e1n MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD (2021) Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 398:2093\u20132100. https:\/\/doi.org\/10.1016\/S0140-6736(21)02249-2","journal-title":"Lancet"},{"key":"12545_CR5","doi-asserted-by":"publisher","first-page":"104936","DOI":"10.1016\/j.antiviral.2020.104936","volume":"183","author":"JM Battagliotti","year":"2020","unstructured":"Battagliotti JM, Fontana D, Etcheverrigaray M, Kratje R, Prieto C (2020) Characterization of hepatitis B virus surface antigen particles expressed in stably transformed mammalian cell lines containing the large, middle and small surface protein. Antiviral Res 183:104936. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104936","journal-title":"Antiviral Res"},{"issue":"10","key":"12545_CR6","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/jphp.12768","volume":"69","author":"D Bertona","year":"2017","unstructured":"Bertona D, Pujato N, Bontempi I, Gonzalez V, Cabrera G, Gugliotta L, Hozbor D, Nicastro A, Calvinho L, Marcipar IS (2017) Development and assessment of a new cage-like particle adjuvant. J Pharm Pharmacol 69(10):1293\u20131303. https:\/\/doi.org\/10.1111\/jphp.12768","journal-title":"J Pharm Pharmacol"},{"key":"12545_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fvets.2020.00396","volume":"7","author":"J Bidart","year":"2020","unstructured":"Bidart J, Kornuta C, Gammella M, Gnazzo V, Soria I, Langellotti C, Mongini C, Galarza R, Calvinho L, Lupi G, Quattrocchi V, Marcipar I, Zamorano P (2020) A new cage-like particle adjuvant enhances protection of foot-and-mouth disease vaccine. Front Vet Sci 7:1\u201312. https:\/\/doi.org\/10.3389\/fvets.2020.00396","journal-title":"Front Vet Sci"},{"key":"12545_CR8","doi-asserted-by":"publisher","first-page":"198339","DOI":"10.1016\/j.virusres.2021.198339","volume":"297","author":"J Bidart","year":"2021","unstructured":"Bidart J, Mignaqui A, Kornuta C, Lupi G, Gammella M, Soria I, Galarza R, Ferella A, Cardillo S, Langellotti C, Quattrocchi V, Durocher Y, Wigdorovitz A, Marcipar I, Zamorano P (2021) FMD empty capsids combined with the immunostimulant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus. Virus Res 297:198339. https:\/\/doi.org\/10.1016\/j.virusres.2021.198339","journal-title":"Virus Res"},{"key":"12545_CR9","doi-asserted-by":"publisher","first-page":"eabp9151","DOI":"10.1126\/sciadv.abp9151","volume":"8","author":"HM Callaway","year":"2022","unstructured":"Callaway HM, Zyla D, Larrous F, de Melo GD, Hastie KM, Avalos RD, Agarwal A, Corti D, Bourhy H, Saphire EO (2022) Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Sci Adv 8:eabp9151. https:\/\/doi.org\/10.1126\/sciadv.abp9151","journal-title":"Sci Adv"},{"key":"12545_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jbiotec.2013.05.001","volume":"166","author":"L Cervera","year":"2013","unstructured":"Cervera L, Guti\u00e9rrez-Granados S, Mart\u00ednez M, Blanco J, G\u00f2dia F, Segura MM (2013) Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium. J Biotechnol 166:152\u2013165. https:\/\/doi.org\/10.1016\/j.jbiotec.2013.05.001","journal-title":"J Biotechnol"},{"key":"12545_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/FIMMU.2022.844837\/BIBTEX","volume":"13","author":"LM Coria","year":"2022","unstructured":"Coria LM, Saposnik LM, Pueblas Castro C, Castro EF, Bruno LA, Stone WB, P\u00e9rez PS, Darriba ML, Chemes LB, Alcain J, Mazzitelli I, Varese A, Salvatori M, Auguste AJ, \u00c1lvarez DE, Pasquevich KA, Cassataro J (2022) A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations containing alum increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection in mice. Front Immunol 13:604. https:\/\/doi.org\/10.3389\/FIMMU.2022.844837\/BIBTEX","journal-title":"Front Immunol"},{"key":"12545_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/V12050513","volume":"12","author":"KHD Crawford","year":"2020","unstructured":"Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD (2020) Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12:513. https:\/\/doi.org\/10.3390\/V12050513","journal-title":"Viruses"},{"key":"12545_CR13","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1001\/JAMA.2020.19759","volume":"324","author":"DM Cutler","year":"2020","unstructured":"Cutler DM, Summers LH (2020) The COVID-19 pandemic and the $16 trillion virus. JAMA 324:1495\u20131496. https:\/\/doi.org\/10.1001\/JAMA.2020.19759","journal-title":"JAMA"},{"key":"12545_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8020294","volume":"8","author":"A Czarnota","year":"2020","unstructured":"Czarnota A, Anna O, Pihl AF, Prentoe J (2020) Specific antibodies induced by immunization with hepatitis B virus-like particles carrying hepatitis C virus envelope glycoprotein 2 epitopes show differential neutralization e ffi ciency. Vaccine 8:1\u201319. https:\/\/doi.org\/10.3390\/vaccines8020294","journal-title":"Vaccine"},{"key":"12545_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.virusres.2016.08.007","volume":"224","author":"M-GA del Carmen","year":"2016","unstructured":"del Carmen M-GA, Rivera-Toledo E, Echeverr\u00eda O, V\u00e1zquez-Nin G, G\u00f3mez B, Bustos-Jaimes I (2016) Peptide presentation on primate erythroparvovirus 1 virus-like particles: in vitro assembly, stability and immunological properties. Virus Res 224:12\u201318. https:\/\/doi.org\/10.1016\/j.virusres.2016.08.007","journal-title":"Virus Res"},{"key":"12545_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","volume":"17","author":"B Donaldson","year":"2018","unstructured":"Donaldson B, Lateef Z, Walker GF, Young SL, Ward VK (2018) Virus-like particle vaccines: immunology and formulation for clinical translation. Expert Rev Vaccines 17:833\u2013849. https:\/\/doi.org\/10.1080\/14760584.2018.1516552","journal-title":"Expert Rev Vaccines"},{"key":"12545_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/ECCO-JCC\/JJW046","volume":"10","author":"O Etzion","year":"2016","unstructured":"Etzion O, Novack V, Perl Y, Abel O, Schwartz D, Munteanu D, Abufreha N, Ben-Yaakov G, Maoz ED, Moshaklo A, Dizingf V, Fich A (2016) Sci-B-VacTM Vs ENGERIX-B vaccines for hepatitis B virus in patients with inflammatory bowel diseases: a randomised controlled trial. J Crohns Colitis 10:905. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJW046","journal-title":"J Crohns Colitis"},{"key":"12545_CR18","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1016\/J.VACCINE.2021.07.034","volume":"39","author":"AC Fluckiger","year":"2021","unstructured":"Fluckiger AC, Ontsouka B, Bozic J, Diress A, Ahmed T, Berthoud T, Tran A, Duque D, Liao M, McCluskie M, Diaz-Mitoma F, Anderson DE, Soare C (2021) An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. Vaccine 39:4988\u20135001. https:\/\/doi.org\/10.1016\/J.VACCINE.2021.07.034","journal-title":"Vaccine"},{"key":"12545_CR19","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.vaccine.2014.02.031","volume":"32","author":"D Fontana","year":"2014","unstructured":"Fontana D, Kratje R, Etcheverrigaray M, Prieto C (2014) Rabies virus-like particles expressed in HEK293 cells. Vaccine 32:2799\u20132804. https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.031","journal-title":"Vaccine"},{"key":"12545_CR20","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1016\/j.vaccine.2015.03.088","volume":"33","author":"D Fontana","year":"2015","unstructured":"Fontana D, Kratje R, Etcheverrigaray M, Prieto C (2015a) Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate. Vaccine 33:4238\u20134246. https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.088","journal-title":"Vaccine"},{"key":"12545_CR21","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1016\/J.VACCINE.2015.03.088","volume":"33","author":"D Fontana","year":"2015","unstructured":"Fontana D, Kratje R, Etcheverrigaray M, Prieto C (2015b) Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate. Vaccine 33:4238\u20134246. https:\/\/doi.org\/10.1016\/J.VACCINE.2015.03.088","journal-title":"Vaccine"},{"key":"12545_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4939-3387-7_7","volume":"1403","author":"D Fontana","year":"2016","unstructured":"Fontana D, Etcheverrigaray M, Kratje R, Prieto C (2016) Development of rabies virus-like particles for vaccine applications: production, characterization, and protection studies. Methods Mol Biol 1403:155\u2013166. https:\/\/doi.org\/10.1007\/978-1-4939-3387-7_7","journal-title":"Methods Mol Biol"},{"key":"12545_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cimid.2019.04.009","volume":"65","author":"D Fontana","year":"2019","unstructured":"Fontana D, Marsili F, Garay E, Battagliotti J, Etcheverrigaray M, Kratje R, Prieto C (2019) A simplified roller bottle platform for the production of a new generation VLPs rabies vaccine for veterinary applications. Comp Immunol Microbiol Infect Dis 65:70\u201375. https:\/\/doi.org\/10.1016\/j.cimid.2019.04.009","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"12545_CR24","doi-asserted-by":"publisher","first-page":"113966","DOI":"10.1016\/j.jviromet.2020.113966","volume":"286","author":"D Fontana","year":"2020","unstructured":"Fontana D, Marsili F, Etcheverrigaray M, Kratje R, Prieto C (2020) Rabies VLPs adjuvanted with saponin-based liposomes induce enhanced immunogenicity mediated by neutralizing antibodies in cattle , dogs and cats. J Virol Methods 286:113966. https:\/\/doi.org\/10.1016\/j.jviromet.2020.113966","journal-title":"J Virol Methods"},{"issue":"3","key":"12545_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/vaccines9030251","volume":"9","author":"D Fontana","year":"2021","unstructured":"Fontana D, Garay E, Cervera L, Kratje R, Prieto C (2021a) Chimeric VLPs based on HIV-1 Gag and a fusion rabies glycoprotein induce specific antibodies against rabies and foot-and-mouth disease virus. Vaccines 9(3):251. https:\/\/doi.org\/10.3390\/vaccines9030251","journal-title":"Vaccines"},{"key":"12545_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/vaccines9030251","volume":"9","author":"D Fontana","year":"2021","unstructured":"Fontana D, Garay E, Cevera L, Kratje R, Prieto C, G\u00f2dia F (2021b) Chimeric vlps based on hiv-1 gag and a fusion rabies glycoprotein induce specific antibodies against rabies and foot-and-mouth disease virus. Vaccines 9:251. https:\/\/doi.org\/10.3390\/vaccines9030251","journal-title":"Vaccines"},{"key":"12545_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00253-021-11747-4","volume":"106","author":"E Garay","year":"2022","unstructured":"Garay E, Fontana D, Leschiutta L, Kratje R, Prieto C (2022) Rational design of novel fusion rabies glycoproteins displaying a major antigenic site of foot-and-mouth disease virus for vaccine applications. Appl Microbiol Biotechnol 106:579\u2013592. https:\/\/doi.org\/10.1007\/s00253-021-11747-4","journal-title":"Appl Microbiol Biotechnol"},{"key":"12545_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/ERV.11.192","volume":"11","author":"N Gar\u00e7on","year":"2012","unstructured":"Gar\u00e7on N, Vaughn DW, Didierlaurent AM (2012) Development and evaluation of AS03, an adjuvant system containing \u03b1-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 11:349\u2013366. https:\/\/doi.org\/10.1586\/ERV.11.192","journal-title":"Expert Rev Vaccines"},{"key":"12545_CR29","doi-asserted-by":"publisher","first-page":"P62","DOI":"10.1186\/1753-6561-7-S6-P62","volume":"7","author":"S Guti\u00e9rrez-Granados","year":"2013","unstructured":"Guti\u00e9rrez-Granados S, Cervera L, G\u00f2dia F, Segura MM (2013) Characterization and quantitation of fluorescent Gag virus-like particles. BMC Proc 7:P62. https:\/\/doi.org\/10.1186\/1753-6561-7-S6-P62","journal-title":"BMC Proc"},{"key":"12545_CR30","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1056\/NEJMOA2201300","volume":"386","author":"KJ Hager","year":"2022","unstructured":"Hager KJ, Marc GP, Gobeil P, Diaz RS, Heizer G, Llapur C, Makarkov AI, Vasconcellos E, Pillet S, Riera F, Saxena P, Wolff PG, Bhutada K, Wallace G, Aazami H, Jones CE, Polack FP, Ferrara L, Atkins J et al (2022) Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine. N Engl J Med 386:2084\u20132096. https:\/\/doi.org\/10.1056\/NEJMOA2201300","journal-title":"N Engl J Med"},{"key":"12545_CR31","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMOA2107659\/SUPPL_FILE\/NEJMOA2107659_DATA-SHARING.PDF","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF et al (2021) Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 385:1172\u20131183. https:\/\/doi.org\/10.1056\/NEJMOA2107659\/SUPPL_FILE\/NEJMOA2107659_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"12545_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1009064","volume":"17","author":"AA Hennrich","year":"2021","unstructured":"Hennrich AA, Sawatsky B, Santos-Mandujano R, Banda DH, Oberhuber M, Schopf A, Pfaffinger V, Wittwer K, Riedel C, Pfaller CK, Conzelmann KK (2021) Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: protection of mice after a single immunization. PLoS Pathog 17:1\u201325. https:\/\/doi.org\/10.1371\/journal.ppat.1009064","journal-title":"PLoS Pathog"},{"key":"12545_CR33","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(21)00528-6","volume":"397","author":"IFN Hung","year":"2021","unstructured":"Hung IFN, Poland GA (2021) Single-dose Oxford\u2013AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet 397:854. https:\/\/doi.org\/10.1016\/S0140-6736(21)00528-6","journal-title":"Lancet"},{"key":"12545_CR34","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/V14102087\/S1","volume":"14","author":"M Jaron","year":"2022","unstructured":"Jaron M, Lehky M, Zar\u00e0 M, Zaydowicz CN, Lak A, Ballmann R, Heine PA, Wenzel EV, Schneider KT, Bertoglio F, Kempter S, K\u00f6ster RW, Barbieri SS, van den Heuvel J, Hust M, D\u00fcbel S, Schubert M (2022) Baculovirus-Free SARS-CoV-2 virus-like particle production in insect cells for rapid neutralization assessment. Viruses 14:2087. https:\/\/doi.org\/10.3390\/V14102087\/S1","journal-title":"Viruses"},{"key":"12545_CR35","doi-asserted-by":"publisher","first-page":"10253","DOI":"10.1523\/JNEUROSCI.0581-12.2012.Soluble","volume":"32","author":"ME Larson","year":"2006","unstructured":"Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider A, Bennett DA, Lesn\u00e9 SE (2006) Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 32:10253\u201310266. https:\/\/doi.org\/10.1523\/JNEUROSCI.0581-12.2012.Soluble","journal-title":"Virology"},{"key":"12545_CR36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","volume":"16","author":"MB Laurens","year":"2020","unstructured":"Laurens MB (2020) RTS,S\/AS01 vaccine (MosquirixTM): an overview. Hum Vaccin Immunother 16:480. https:\/\/doi.org\/10.1080\/21645515.2019.1669415","journal-title":"Hum Vaccin Immunother"},{"key":"12545_CR37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/FBIOE.2020.00617","volume":"8","author":"J Lavado-Garc\u00eda","year":"2020","unstructured":"Lavado-Garc\u00eda J, Cervera L, G\u00f2dia F (2020) An alternative perfusion approach for the intensification of virus-like particle production in HEK293 cultures. Front Bioeng Biotechnol 8:617. https:\/\/doi.org\/10.3389\/FBIOE.2020.00617","journal-title":"Front Bioeng Biotechnol"},{"issue":"12","key":"12545_CR38","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1007\/s00253-017-8246-0","volume":"101","author":"X Liu","year":"2017","unstructured":"Liu X, Fang Y, Zhou P, Lu Y, Zhang Q, Xiao S, Dong Z, Pan L, Lv J, Zhang Z, Zhang Y, Wang Y (2017) Chimeric virus-like particles elicit protective immunity against serotype O foot-and-mouth disease virus in guinea pigs. Appl Microbiol Biotechnol 101(12):4905\u20134914. https:\/\/doi.org\/10.1007\/s00253-017-8246-0","journal-title":"Appl Microbiol Biotechnol"},{"key":"12545_CR39","doi-asserted-by":"publisher","first-page":"100967","DOI":"10.1016\/J.ACCPM.2021.100967","volume":"40","author":"P Loubet","year":"2021","unstructured":"Loubet P, Laureillard D, Martin A, Larcher R, Sotto A (2021) Why promoting a COVID-19 vaccine booster dose? Anaesth Crit Care Pain Med 40:100967. https:\/\/doi.org\/10.1016\/J.ACCPM.2021.100967","journal-title":"Anaesth Crit Care Pain Med"},{"key":"12545_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/bit.25159","volume":"111","author":"LHL Lua","year":"2014","unstructured":"Lua LHL, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg APJ (2014) Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 111:425\u2013440. https:\/\/doi.org\/10.1002\/bit.25159","journal-title":"Biotechnol Bioeng"},{"key":"12545_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00253-015-6973-7","volume":"100","author":"VA Mareze","year":"2016","unstructured":"Mareze VA, Borio CS, Bilen MF, Fleith R, Mirazo S, Mansur DS, Arbiza J, Lozano ME, Bru\u00f1a-Romero O (2016) Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences. Appl Microbiol Biotechnol 100:125\u2013133. https:\/\/doi.org\/10.1007\/s00253-015-6973-7","journal-title":"Appl Microbiol Biotechnol"},{"key":"12545_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/HIS.14134","volume":"77","author":"T Menter","year":"2020","unstructured":"Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S, Turek D, Willi N, Pargger H, Bassetti S, Leuppi JD, Cathomas G, Tolnay M, Mertz KD, Tzankov A (2020) Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 77:198\u2013209. https:\/\/doi.org\/10.1111\/HIS.14134","journal-title":"Histopathology"},{"key":"12545_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","volume":"34","author":"MO Mohsen","year":"2017","unstructured":"Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF (2017) Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines. Semin Immunol 34:123\u2013132. https:\/\/doi.org\/10.1016\/j.smim.2017.08.014","journal-title":"Semin Immunol"},{"key":"12545_CR44","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMOA2034577\/SUPPL_FILE\/NEJMOA2034577_PROTOCOL.PDF","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMOA2034577\/SUPPL_FILE\/NEJMOA2034577_PROTOCOL.PDF","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"12545_CR45","doi-asserted-by":"publisher","first-page":"P7","DOI":"10.1186\/1753-6561-5-S8-P7","volume":"5","author":"C Prieto","year":"2011","unstructured":"Prieto C, Fontana D, Etcheverrigaray M, Kratje R (2011) A strategy to obtain recombinant cell lines with high expression levels. Lentiviral vector-mediated transgenesis. BMC Proc 5(Suppl 8):P7. https:\/\/doi.org\/10.1186\/1753-6561-5-S8-P7","journal-title":"BMC Proc"},{"key":"12545_CR46","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/ALL.15311","volume":"77","author":"DA Rothen","year":"2022","unstructured":"Rothen DA, Krenger PS, Nonic A, Balke I, Vogt ACS, Chang X, Manenti A, Vedovi F, Resevica G, Walton SM, Zeltins A, Montomoli E, Vogel M, Bachmann MF, Mohsen MO (2022) Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern. Allergy 77:2446\u20132458. https:\/\/doi.org\/10.1111\/ALL.15311","journal-title":"Allergy"},{"key":"12545_CR47","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMOA2034201\/SUPPL_FILE\/NEJMOA2034201_DATA-SHARING.PDF","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans P-J, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ et al (2021) Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 384:1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMOA2034201\/SUPPL_FILE\/NEJMOA2034201_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"12545_CR48","doi-asserted-by":"publisher","first-page":"F123","DOI":"10.1016\/J.VACCINE.2012.04.108","volume":"30","author":"JT Schiller","year":"2012","unstructured":"Schiller JT, Castellsagu\u00e9 X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:F123. https:\/\/doi.org\/10.1016\/J.VACCINE.2012.04.108","journal-title":"Vaccine"},{"key":"12545_CR49","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682. https:\/\/doi.org\/10.1038\/nmeth.2019","journal-title":"Nat Methods"},{"key":"12545_CR50","doi-asserted-by":"publisher","first-page":"101603","DOI":"10.1016\/J.XPRO.2022.101603","volume":"3","author":"V Stalls","year":"2022","unstructured":"Stalls V, Janowska K, Acharya P (2022) Transient transfection and purification of SARS-CoV-2 spike protein from mammalian cells. STAR Protoc 3:101603. https:\/\/doi.org\/10.1016\/J.XPRO.2022.101603","journal-title":"STAR Protoc"},{"issue":"10","key":"12545_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-78656-w","volume":"101","author":"H Swann","year":"2020","unstructured":"Swann H, Sharma A, Preece B, Peterson A, Eldridge C, Belnap DM, Vershinin M (2020) Saffarian S (2020) Minimal system for assembly of SARS-CoV-2 virus like particles. Sci Rep 101(10):1\u20135. https:\/\/doi.org\/10.1038\/s41598-020-78656-w","journal-title":"Sci Rep"},{"issue":"6","key":"12545_CR52","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","volume":"17","author":"W Tai","year":"2020","unstructured":"Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L (2020) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17(6):613\u2013620. https:\/\/doi.org\/10.1038\/s41423-020-0400-4","journal-title":"Cell Mol Immunol"},{"key":"12545_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, G\u00fcner HR, Azap A, Akhan S, K\u00f6se \u015e, Erdin\u00e7 F\u015e, Akal\u0131n EH, Tabak \u00d6F, Pulluk\u00e7u H, Batum \u00d6, \u015eim\u015fek Yavuz S, Turhan \u00d6, Y\u0131ld\u0131rmak MT, K\u00f6ksal \u0130, Ta\u015fova Y, Korten V, Y\u0131lmaz G et al (2021) Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet (London, England) 398:213\u2013222. https:\/\/doi.org\/10.1016\/S0140-6736(21)01429-X","journal-title":"Lancet (London, England)"},{"key":"12545_CR54","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S0140-6736(20)31185-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel A, Mehra MR, Scholkmann F, Sch\u00fcpbach R, Ruschitzka F, Moch H (2020) Electron microscopy of SARS-CoV-2: a challenging task \u2013 Authors\u2019 reply. Lancet 395:e100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31185-5","journal-title":"Lancet"},{"key":"12545_CR55","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1016\/j.vaccine.2016.04.089","volume":"34","author":"A Venereo-Sanchez","year":"2016","unstructured":"Venereo-Sanchez A, Gilbert R, Simoneau M, Caron A, Chahal P, Chen W, Ansorge S, Li X, Henry O, Kamen A (2016) Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: an effective influenza vaccine candidate. Vaccine 34:3371\u20133380. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.089","journal-title":"Vaccine"},{"key":"12545_CR56","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1016\/j.vaccine.2019.07.057","volume":"37","author":"A Venereo-S\u00e1nchez","year":"2019","unstructured":"Venereo-S\u00e1nchez A, Fulton K, Koczka K, Twine S, Chahal P, Ansorge S, Gilbert R, Henry O, Kamen A (2019) Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF. Vaccine 37:7100\u20137107. https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.057","journal-title":"Vaccine"},{"key":"12545_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"12545_CR58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"180","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park Y, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS- CoV-2 spike glycoprotein. Cell 180:281\u2013292","journal-title":"Cell"},{"issue":"9","key":"12545_CR59","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/s1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (2022) Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 22(9):1293\u20131302. https:\/\/doi.org\/10.1016\/s1473-3099(22)00320-6","journal-title":"Lancet Infect Dis"},{"key":"12545_CR60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis 21:39\u201351. https:\/\/doi.org\/10.1016\/S1473-3099(20)30831-8","journal-title":"Lancet Infect Dis"},{"key":"12545_CR61","doi-asserted-by":"publisher","first-page":"12973","DOI":"10.1038\/srep12973","volume":"5","author":"L Xu","year":"2015","unstructured":"Xu L, He D, Yang L, Li Z, Ye X, Yu H, Zhao H, Li S, Yuan L, Qian H, Que Y, Kuo Shih JW, Zhu H, Li Y, Cheng T, Xia N (2015) A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of Enterovirus 71. Sci Rep 5:12973. https:\/\/doi.org\/10.1038\/srep12973","journal-title":"Sci Rep"},{"key":"12545_CR62","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fbioe.2020.00862","volume":"8","author":"R Xu","year":"2020","unstructured":"Xu R, Shi M, Li J, Song P, Li N (2020) Construction of SARS-CoV-2 virus-like particles by mammalian expression system. Front Bioeng Biotechnol 8:862. https:\/\/doi.org\/10.3389\/fbioe.2020.00862","journal-title":"Front Bioeng Biotechnol"},{"issue":"17","key":"12545_CR63","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","volume":"176","author":"C Yi","year":"2020","unstructured":"Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, Qu A, Xu J, Shi Z, Ling Z (2020) Sun B (2020) Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol 176(17):621\u2013630. https:\/\/doi.org\/10.1038\/s41423-020-0458-z","journal-title":"Cell Mol Immunol"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-023-12545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00253-023-12545-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-023-12545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:03:02Z","timestamp":1683824582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00253-023-12545-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["12545"],"URL":"https:\/\/doi.org\/10.1007\/s00253-023-12545-w","relation":{},"ISSN":["0175-7598","1432-0614"],"issn-type":[{"value":"0175-7598","type":"print"},{"value":"1432-0614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"2 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The immunization protocols were approved and supervised by the Advisory Committee on Ethics and Security of the School of Biochemistry and Biological Sciences, Universidad Nacional del Litoral, according to international guidelines (\u201cGuide for the Care and Use of Laboratory Animals,\u201d Eighth Edition National Research Council 2011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}